JP2014521659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521659A5 JP2014521659A5 JP2014523093A JP2014523093A JP2014521659A5 JP 2014521659 A5 JP2014521659 A5 JP 2014521659A5 JP 2014523093 A JP2014523093 A JP 2014523093A JP 2014523093 A JP2014523093 A JP 2014523093A JP 2014521659 A5 JP2014521659 A5 JP 2014521659A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- lactose
- composition further
- filler
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000905 isomalt Substances 0.000 claims 1
- 235000010439 isomalt Nutrition 0.000 claims 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 239000002265 redox agent Substances 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512817P | 2011-07-28 | 2011-07-28 | |
| US61/512,817 | 2011-07-28 | ||
| PCT/US2012/048689 WO2013016686A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209185A Division JP2017061482A (ja) | 2011-07-28 | 2016-10-26 | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521659A JP2014521659A (ja) | 2014-08-28 |
| JP2014521659A5 true JP2014521659A5 (https=) | 2015-08-20 |
Family
ID=47597382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523093A Withdrawn JP2014521659A (ja) | 2011-07-28 | 2012-07-27 | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
| JP2016209185A Withdrawn JP2017061482A (ja) | 2011-07-28 | 2016-10-26 | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016209185A Withdrawn JP2017061482A (ja) | 2011-07-28 | 2016-10-26 | ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20130028866A1 (https=) |
| EP (1) | EP2736336A4 (https=) |
| JP (2) | JP2014521659A (https=) |
| KR (1) | KR20140054129A (https=) |
| CN (1) | CN103781355A (https=) |
| AU (2) | AU2012286701A1 (https=) |
| BR (1) | BR112014002092A2 (https=) |
| CA (1) | CA2843432A1 (https=) |
| EA (1) | EA201490378A1 (https=) |
| HK (1) | HK1198278A1 (https=) |
| MX (1) | MX2014001048A (https=) |
| SG (1) | SG10201606204TA (https=) |
| TW (1) | TW201726137A (https=) |
| UY (1) | UY34359A (https=) |
| WO (1) | WO2013016686A1 (https=) |
| ZA (1) | ZA201401217B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| JP5819328B2 (ja) | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
| CN102791130B (zh) * | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| FR2988058B1 (fr) | 2012-03-15 | 2014-10-03 | A Fermetures As | Dispositif de calage a quai de vehicule de transport de marchandises |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| EA201591507A1 (ru) * | 2013-02-15 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза лахинимодом |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2015017690A1 (en) * | 2013-08-01 | 2015-02-05 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| US10844416B2 (en) * | 2015-06-01 | 2020-11-24 | Biogen Ma Inc. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
| US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| JP2009507003A (ja) * | 2005-09-01 | 2009-02-19 | アレス トレーディング ソシエテ アノニム | 視神経炎の治療 |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| US20110195049A1 (en) * | 2008-10-13 | 2011-08-11 | Biovista, Inc. | Compositions and methods for treating multiple sclerosis |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
| EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
| EA201692180A1 (ru) * | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
-
2012
- 2012-07-27 WO PCT/US2012/048689 patent/WO2013016686A1/en not_active Ceased
- 2012-07-27 EP EP12817547.8A patent/EP2736336A4/en not_active Withdrawn
- 2012-07-27 JP JP2014523093A patent/JP2014521659A/ja not_active Withdrawn
- 2012-07-27 US US13/560,872 patent/US20130028866A1/en not_active Abandoned
- 2012-07-27 SG SG10201606204TA patent/SG10201606204TA/en unknown
- 2012-07-27 HK HK14111811.8A patent/HK1198278A1/xx unknown
- 2012-07-27 EA EA201490378A patent/EA201490378A1/ru unknown
- 2012-07-27 CA CA2843432A patent/CA2843432A1/en not_active Abandoned
- 2012-07-27 BR BR112014002092A patent/BR112014002092A2/pt not_active IP Right Cessation
- 2012-07-27 MX MX2014001048A patent/MX2014001048A/es unknown
- 2012-07-27 KR KR1020147004932A patent/KR20140054129A/ko not_active Withdrawn
- 2012-07-27 CN CN201280043782.6A patent/CN103781355A/zh active Pending
- 2012-07-27 AU AU2012286701A patent/AU2012286701A1/en not_active Abandoned
- 2012-10-01 TW TW105134805A patent/TW201726137A/zh unknown
- 2012-10-01 UY UY0001034359A patent/UY34359A/es not_active Application Discontinuation
-
2014
- 2014-02-18 ZA ZA2014/01217A patent/ZA201401217B/en unknown
- 2014-10-29 US US14/527,199 patent/US20150056281A1/en not_active Abandoned
-
2016
- 2016-02-22 US US15/050,005 patent/US20160166648A1/en not_active Abandoned
- 2016-07-13 AU AU2016204909A patent/AU2016204909A1/en not_active Abandoned
- 2016-10-26 JP JP2016209185A patent/JP2017061482A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521659A5 (https=) | ||
| JP2015525757A5 (https=) | ||
| JP2013520167A5 (https=) | ||
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| JP2012067110A5 (https=) | ||
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| NZ604055A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| HRP20180591T1 (hr) | Inhibitori kinaze serina ili treonina | |
| JP2011105738A5 (https=) | ||
| JP2015512729A5 (https=) | ||
| JP2012501986A5 (https=) | ||
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| JP2014515597A5 (https=) | ||
| JP2014530840A5 (https=) | ||
| JP2012036197A5 (https=) | ||
| JP2009537554A5 (https=) | ||
| JP2014221827A5 (https=) | ||
| JP2010282906A5 (https=) | ||
| JP2013539979A5 (https=) | ||
| JP2014518280A5 (https=) | ||
| JP2012501302A5 (https=) | ||
| JP2017014205A5 (https=) | ||
| JP2012111729A5 (https=) | ||
| JP2008505075A5 (https=) | ||
| TH90965B (th) | เครื่องเล่นแผ่นดิสก์ |